Patient-Powered Drug Trials Are Getting The FDA Greenlight
By Sunitha Malepati, founder, and Craig Lipset, head of clinical innovation, Buffalo Initiative, a program of Renaissance Philanthropy
A parent-led nonprofit developed a gene therapy and secured FDA clearance to take it into humans.
On January 24, 2026, the FOXG1 Research Foundation announced that the FDA has authorized a first-in-human, multisite clinical trial of a gene replacement therapy that the foundation itself developed and sponsors. The nonprofit, started and run by parents of children with the rare neurodevelopmental FOXG1 syndrome, announced this latest milestone following prior FDA Orphan Drug and Rare Pediatric Disease designations for the therapy.
This is a feel-good story, but more importantly, it’s a much-needed step in drug development. And the FOXG1 Foundation isn’t an outlier. Parent-led organizations like the TESS Research Foundation, advancing a gene therapy for SLC13A5 deficiency, and the INADcure Foundation, developing a gene therapy for infantile neuroaxonal dystrophy (INAD), are following similar paths. These programs would not exist without parents stepping into roles traditionally reserved for biotech companies. These organizations are actively challenging the basic assumption about who can — and should — develop medicines.
The Old Playbook Is Breaking
For decades, the unspoken structure of rare disease drug development has been simple: Academic researchers discover. Pharmaceutical companies develop. Patients wait.
When a disease affects only a few hundred or a few thousand people worldwide, the commercial math often fails. The biology may be compelling, the target is validated, and the preclinical is data is strong, but company investors deem the market too small, too risky, or too slow. Entire communities are left waiting for industry to decide their disease is “worth it.”
Parents and patients are no longer willing to wait.
Across rare diseases, patient organizations are stepping into roles once reserved exclusively for industry. They're moving beyond raising awareness and providing lived-experience insights and are now hiring seasoned drug developers, running preclinical programs, filing INDs, manufacturing investigational therapies, and sponsoring clinical trials. Some partner with academic labs or biotech firms, while others operate independently. In each case, they are doing the work because no one else would. They follow the same FDA pathways, the same GMP requirements, and the same scientific standards as any biotech company.
Why This Works
Drug development is expensive, complex, and unforgiving, so any skepticism would be understandable. Can parents really do this?
Scientific rigor doesn’t come from a corporate logo; it comes from expertise and commitment to process. Patient groups can bring both. Patient organizations hire the same expertise as industry: regulatory consultants, toxicologists, CMC specialists, clinical trialists.
Concerns about bias misunderstand the incentives. Parents want treatments desperately, but they also understand that unsafe or ineffective drugs help no one. Unlike traditional companies, these groups aren’t driven by quarterly earnings or exit timelines. Their accountability runs directly to the patient community.
Patient groups are also unusually efficient. Without layers of corporate bureaucracy, patient-led teams move quickly, adopt platform approaches, and make pragmatic decisions. FDA innovations, including flexibility for ultra-rare diseases and pathways based on strong mechanistic rationale, are often easier for these groups to use than for larger companies constrained by precedent and scale.
The Invisible Pipeline
Despite their growing role, drug programs led by patient groups remain largely invisible to the broader ecosystem.
In traditional biopharma, investors, researchers, and companies rely on detailed subscription databases to track therapeutic pipelines. These tools help identify promising assets, collaboration opportunities, and acquisition targets. No databases exist for patient-led programs, and that invisibility has consequences.
Without a clear view of what exists, it’s impossible to see where programs stall, where shared manufacturing or regulatory support could help, or where capital could be deployed most effectively. These efforts are treated as isolated exceptions rather than a coherent, growing segment of drug development.
That’s why the Buffalo Initiative recently launched the first publicly accessible pipeline tracking therapeutic programs led by patient groups. Visibility isn’t about recognition for its own sake. It’s a prerequisite for investment.
From Charity To Capital
A common response to parent-led drug development is admiration paired with skepticism: inspiring, but not scalable. That’s only true if we continue to treat these efforts as charity cases rather than as a legitimate asset class. We need to acknowledge a reality that the system has been slow to accept: Without parent and patient entrepreneurs, many of these therapies would not exist at all. The FOXG1 trial emerged from an invisible pipeline built by patient groups who refused to wait, and it won’t be the last if we choose to see and support what they’re building.
About The Authors:
Sunitha Malepati is the founder of the Buffalo Initiative, a program of Renaissance Philanthropy. The Buffalo Initiative supports patient-led therapeutic development for ultra-rare diseases. Renaissance Philanthropy is a nonprofit organization that focuses on increasing ambition in science, technology, and innovation. We build time-bound, thesis-driven philanthropic funds that enable donors and foundations to support ideas that advance entire fields forward.
Craig Lipset is head of clinical innovation for the Buffalo Initiative. The Buffalo Initiative supports patient-led therapeutic development for ultra-rare diseases. Renaissance Philanthropy is a nonprofit organization that focuses on increasing ambition in science, technology, and innovation. We build time-bound, thesis-driven philanthropic funds that enable donors and foundations to support ideas that advance entire fields forward.